Roy Mano

Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks

Using tumour phylogenetics to identify the roots of metastasis in humans

Mechanisms of hypoxia signalling: new implications for nephrology

Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Targeting HIF2 in Clear Cell Renal Cell Carcinoma

Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection

The immune contexture in cancer prognosis and treatment

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation

Emerging Biological Principles of Metastasis

Urothelial carcinoma management in elderly or unfit patients

VHL and Kidney Cancer

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours

Metastatic colonization by circulating tumour cells

Renal cell carcinoma

Tumour heterogeneity and resistance to cancer therapies

HIF activation identifies early lesions in VHL kidneys

An intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells

Long Noncoding RNA and Cancer: A New Paradigm

Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL ^−/− clear cell renal carcinoma

Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor

The von Hippel-Lindau Tumor Suppressor Gene

Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma

Neutrophil‐to‐lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710

Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity

TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype

Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non–muscle-invasive bladder cancer

Treatment patterns and outcomes in “real world” patients (pts) with metastatic urothelial cancer (UC).

The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling